ATE136215T1 - Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden - Google Patents

Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden

Info

Publication number
ATE136215T1
ATE136215T1 AT90903464T AT90903464T ATE136215T1 AT E136215 T1 ATE136215 T1 AT E136215T1 AT 90903464 T AT90903464 T AT 90903464T AT 90903464 T AT90903464 T AT 90903464T AT E136215 T1 ATE136215 T1 AT E136215T1
Authority
AT
Austria
Prior art keywords
prevention
composition
repair
fibrotic
fibrotic damage
Prior art date
Application number
AT90903464T
Other languages
German (de)
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE136215T1 publication Critical patent/ATE136215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT90903464T 1989-02-15 1990-01-26 Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden ATE136215T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1035436A JPH02215719A (ja) 1989-02-15 1989-02-15 線維化病変組織の修復並びに線維化病変の阻止剤

Publications (1)

Publication Number Publication Date
ATE136215T1 true ATE136215T1 (de) 1996-04-15

Family

ID=12441800

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90903464T ATE136215T1 (de) 1989-02-15 1990-01-26 Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden

Country Status (9)

Country Link
EP (3) EP0458861B1 (enExample)
JP (1) JPH02215719A (enExample)
AT (1) ATE136215T1 (enExample)
AU (1) AU633541B2 (enExample)
CA (1) CA2010017C (enExample)
DE (2) DE69033863T2 (enExample)
DK (1) DK0458861T3 (enExample)
ES (2) ES2163389T3 (enExample)
WO (1) WO1990009176A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
ATE224712T1 (de) * 1993-05-07 2002-10-15 Solomon B Margolin Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
ES2220975T3 (es) * 1995-03-03 2004-12-16 Solomon B. Margolin Tratamiento de trastornos producidos por factores de crecimiento de citoquina.
WO2000016775A1 (en) * 1998-09-18 2000-03-30 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101484167B (zh) 2006-06-15 2012-07-04 上海睿星基因技术有限公司 吡啶酮类衍生物预防和治疗放射性肺损伤的用途
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
WO2010045871A1 (en) * 2008-10-21 2010-04-29 Dieretech Investment Limited Composition and method for treating proteinuria
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
BR112013022766A2 (pt) 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
JP5872564B2 (ja) * 2011-09-14 2016-03-01 塩野義製薬株式会社 吸入用医薬組成物
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
JP6454348B2 (ja) * 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
WO2016122420A1 (en) 2015-01-26 2016-08-04 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
MX2020005775A (es) * 2020-07-13 2022-01-14 Centro De Retina Medica Y Quirurgica S C Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (enExample) * 1967-12-01 1969-06-03
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
US3644626A (en) * 1969-11-25 1972-02-22 Merck & Co Inc Novel pyridones in compositions and methods for treating inflammation pain and fever
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤

Also Published As

Publication number Publication date
EP0458861A4 (en) 1992-07-08
JPH0552814B2 (enExample) 1993-08-06
DE69033863D1 (de) 2002-01-03
CA2010017A1 (en) 1990-08-15
EP0383591A2 (en) 1990-08-22
EP1138329A3 (en) 2002-04-17
DE69034143D1 (de) 2004-07-08
DE69033863T2 (de) 2002-06-13
EP0383591A3 (en) 1992-01-15
EP1138329A2 (en) 2001-10-04
JPH02215719A (ja) 1990-08-28
WO1990009176A1 (en) 1990-08-23
AU633541B2 (en) 1993-02-04
EP0458861B1 (en) 1996-04-03
EP1138329B1 (en) 2004-06-02
DE69034143T2 (de) 2005-06-30
ES2220612T3 (es) 2004-12-16
AU4981290A (en) 1990-08-23
DK0458861T3 (da) 1996-08-12
CA2010017C (en) 1995-09-05
EP0383591B1 (en) 2001-11-21
ES2163389T3 (es) 2002-02-01
EP0458861A1 (en) 1991-12-04
EP1138329B8 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
DE69033863D1 (de) Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen
DK407483A (da) Antibakterielle naphthyridin-, quinolin- og benzoxazincarboxylsyrer, fremgangsmaader til deres fremstilling, deres anvendelse og mellemprodukter anvendelige ved forbindelsernes fremstilling
FI942112L (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
EP0266576A3 (en) 1-tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents
DE69132006D1 (de) Thiazolederivate als inhibitoren von aktivem sauerstoff
ES2033442T3 (es) Procedimiento para preparar una composicion farmaceutica a base de acidos grasos.
DK176687D0 (da) Lipolytiske enzymer og deres anvendelse i detergentkompositioner
NZ227680A (en) Quinoline and naphthyridine derivatives, intermediates and pharmaceutical compositions
FI935020A7 (fi) Interleukiini-1b-proteaasi ja interleukiini-1b-proteaasin inhibiittoreita
ATE190503T1 (de) Pharmazeutisches präparat enthaltend glucosidase- und/oder amylasehemmer und einen lipasehemmer
FI19992420L (fi) Mikrobifytaasin kloonaus ja ilmentäminen
FI855117L (fi) Segmenttipolyestereitä ja niiden kaltaisia yhdisteitä käytettäviksi lianirrotusaineina pesuainekoostumuksissa
FI913142A0 (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
EP0273689A3 (en) Derivatives of n-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors
GR1001218B (el) Μεθοδος παρασκευης αλατων κεφαλοσπορινης και ενεσιμων συνθεσεων
ATE92717T1 (de) Verfahren zur verbesserung der wirksamkeit von insektentoxinen.
KR880700673A (ko) 골손상 치료용방법 및 조성물
AU642537B2 (en) 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
FI925947A7 (fi) Uusia heterosyklisiä 2-sakkarinyylimetyylikarboksylaatteja, jotka ovatkäyttökelpoisia proteolyyttisten entsyymien inhibiittoreina, niitä sisältäviä koostumuksia ja niiden käyttö
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
FI911269A7 (fi) Menetelmä ja koostumus aktiivisten aineiden lisääntyneen pitoisuuden aikaansaamiseksi iholla iontoforeesin avulla
EE9600044A (et) Püranooni derivaadid kui proteaasi inhibiitorid ja viirusevastased toimeained
AT388949B (de) Fahrbare gleisbearbeitungsmaschine fuer den weichen- und kreuzungsbereich
DE59303284D1 (de) Vorrichtung zur Schadensverhinderung an Gebäuden in Bereichen von Bodenbewegungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time